Drug

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation
DiabetesHKG: 6887

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that the China National Medical Products Administration (NMPA) has granted marketing approval for its Insulin Degludec and Insulin Aspart Injection, a dual…

Hengrui Pharma's Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market

Hengrui Pharma’s Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market

Bayer's Finerenone Advances Toward FDA Approval for Non‑Diabetic CKD – sNDA Accepted Based on Phase III FIND‑CKD Data

Bayer’s Finerenone Advances Toward FDA Approval for Non‑Diabetic CKD – sNDA Accepted Based on Phase III FIND‑CKD Data

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BeOne MedicinesClinical trial approval / initiation

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

AstraZenecaMarket approval filings

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Avistone Pharmaceuticals BiotechnologyCancer

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
BeOne MedicinesCombination therapy

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Show More